Why Biocryst Pharmaceuticals Inc. (BCRX) Should Be On Your Radar Moving Forward

The stock of Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) last traded at $6.47, up 1.73% from the previous session.

BCRX stock price is now 31.86% away from the 50-day moving average and 10.42% away from the 200-day moving average. The market capitalization of the company currently stands at $1.34B.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


On September 18, 2023, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $9 to quote $10, while ‘Jefferies’ rates the stock as ‘Buy’

In other news, Doyle Anthony, Chief Financial Officer bought 36,300 shares of the company’s stock on May 14 ’24. The stock was bought for $202,191 at an average price of $5.57. Upon completion of the transaction, the Chief Financial Officer now directly owns 266,744 shares in the company, valued at $1.73 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 14 ’24, Chief R&D Officer Thackray Helen M. bought 30,000 shares of the business’s stock. A total of $175,800 was incurred on buying the stock at an average price of $5.86. This leaves the insider owning 272,139 shares of the company worth $1.76 million. A total of 3.68% of the company’s stock is owned by insiders.

During the past 12 months, Biocryst Pharmaceuticals Inc. has had a low of $4.03 and a high of $8.96.

According to the Biotechnology Company, earnings per share came in at -0.4, missing analysts’ expectations of -0.23 by -0.17. This compares to -$0.28 EPS in the same period last year. The company reported revenue of $92.76 million for the quarter, compared to $68.78 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.87 percent. For the current quarter, analysts expect BCRX to generate $98.47M in revenue.

Related Posts